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Abstract
Background: Microglia, the principle immune cells of the brain, play important roles in neuronal development,
homeostatic function and neurodegenerative disease. Recent genetic studies have further highlighted the importance
of microglia in neurodegeneration with the identification of disease risk polymorphisms in many microglial genes. To
better understand the role of these genes in microglial biology and disease, we, and others, have developed methods
to differentiate microglia from human induced pluripotent stem cells (iPSCs). While the development of these methods
has begun to enable important new studies of microglial biology, labs with little prior stem cell experience have
sometimes found it challenging to adopt these complex protocols. Therefore, we have now developed a greatly
simplified approach to generate large numbers of highly pure human microglia.
Results: iPSCs are first differentiated toward a mesodermal, hematopoietic lineage using commercially available media.
Highly pure populations of non-adherent CD43+ hematopoietic progenitors are then simply transferred to media that
includes three key cytokines (M-CSF, IL-34, and TGFβ-1) that promote differentiation of homeostatic microglia. This
updated approach avoids the prior requirement for hypoxic incubation, complex media formulation, FACS sorting, or co-
culture, thereby significantly simplifying human microglial generation. To confirm that the resulting cells are equivalent to
previously developed iPSC-microglia, we performed RNA-sequencing, functional testing, and transplantation studies. Our
findings reveal that microglia generated via this simplified method are virtually identical to iPS-microglia produced via our
previously published approach. To also determine whether a small molecule activator of TGFβ signaling (IDE1) can be
used to replace recombinant TGFβ1, further reducing costs, we examined growth kinetics and the transcriptome of cells
differentiated with IDE1. These data demonstrate that a microglial cell can indeed be produced using this alternative
approach, although transcriptional differences do occur that should be considered.
Conclusion: We anticipate that this new and greatly simplified protocol will enable many interested labs, including those
with little prior stem cell or flow cytometry experience, to generate and study human iPS-microglia. By combining this
method with other advances such as CRISPR-gene editing and xenotransplantation, the field will continue to improve our
understanding of microglial biology and their important roles in human development, homeostasis, and disease.
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Background
Microglia are highly specialized tissue resident macro-
phages within the brain. Their homeostatic functions
include shaping neural circuits through promotion of
neuronal growth and differentiation as well as synaptic
pruning. Microglia have also been strongly implicated in
a number of neurological diseases and injuries. Most re-
cently, genetic studies have identified many genes that
are highly expressed in microglia which are associated
with altered risk of developing Alzheimer’s disease (AD),
Parkinson’s disease, Frontotemporal Dementia, or
Amyolateral Sclerosis [1–4]. These new discoveries have
placed microglia and neuroinflammation at the forefront
of disease progression emphasizing the need for new
model systems to enable the study of human microglia.
Yet, microglia have proven to be difficult cells to study
given that many differences exist between human and
murine microglia [5]. Additionally, there are significant
challenges in isolating and culturing these cells [6, 7].
Primary human microglia can be isolated in relatively
limited numbers from postmortem brain tissue or
following surgical resection of brain tumors or epileptic
foci. However, given the considerable sensitivity of
microglia to environmental changes, samples isolated
from patients with neurological disease or following the
agonal state prior to death, are likely to be activated and
may differ depending on disease state, comorbidities, or
cause of death. In order to study a more homeostatic
human microglia and to utilize modern experimental
manipulations such as CRISPR gene editing, many
scientists have instead turned to induced pluripotent
stem cells (iPSCs).
In the past 3 years, several labs, including our own,
have developed various protocols for differentiating
microglia-like cells from pluripotent stem cells [8–13].
While the purity, yield, and reproducibility of these dif-
ferent approaches varies considerably, each of these
methods produces myeloid cells that exhibit transcrip-
tional profiles and many key functional or morphological
characteristics of human microglia. However, the rela-
tively complex nature of these protocols has made it
challenging for labs new to stem cell culture or those
lacking fluorescence-associated cell-sorting (FACS) core
facilities to quickly adopt these approaches. We have
therefore developed an appreciably simplified method
(iPS-microglia 2.0) to produce both large numbers and
highly purified cultures of human microglia. The re-
sulting cells exhibit RNA transcript profiles that are
nearly identical to iPS-microglia generated using our
previously published protocol [8], but provide a signifi-
cantly increased yield at a reduced cost and omit the
prior need for a hypoxic incubator and FACS capa-
bilities, making the protocol more readily accessible for
a wider variety of labs.
Results
The transcriptome of iPS-microglia 2.0 differentiated
without hypoxia or cell sorting are almost identical to
those generated using our prior approach
Our new differentiation protocol still mimics in vivo
microglia ontogeny by first differentiating iPSCs into
hematopoietic progenitor cells (HPCs), followed by
passage into microglial differentiation medium, and con-
cludes with a final maturation step by adding neural and
astrocytic factors, thereby educating the microglia in a
brain-like environment while maintaining a pure,
homeostatic population of microglia (Fig. 1).
In order to test whether or not an extensively simpli-
fied and commercially available hematopoietic stem cell
differentiation protocol could be used to generate
equivalent homeostatic microglia, we differentiated four
independent iPSC lines, and one ESC line (H9) in paral-
lel using our previously published protocol [8]
(iPS-microglia) and the simplified iPS-microglia 2.0
protocol described here. Our prior protocol required
FACS to isolate CD43+ hematopoietic progenitors before
transitioning to microglial differentiation medium con-
taining IL-34, TGFβ-1, and M-CSF [14–16]. To deter-
mine whether FACS sorting was also necessary for our
newer approach, we compared three different sorting
methods on the same iPSC background. On day 11
when HPCs were ready to be transitioned into microglial
medium, we isolated CD43+ HPCs using either FACS,
magnetic-activated cell sorting (MACS), or by simply
collecting all non-adherent cells. After analyzing tran-
scriptome changes through RNA-sequencing on these
samples, we performed unbiased clustering and found
that FACS- and MACS-sorted iPS-microglia 2.0 intercluster
with unsorted samples demonstrating that these isolation
procedures are not necessary for this updated protocol
(Additional file 1: Figure S1). Notably, one of the first results
we observed with this simplified protocol was that the num-
ber of CD43+ HPCs produced using this novel commer-
cially available method was substantially increased, while
still maintaining the high degree of purity (90–94%) for the
HPC marker CD43 (Additional file 2: Figure S2). From one
million starting iPS cells, 125 million CD43+ cells can be
produced, representing an approximately 60-fold increase
over our prior method. Following transition to microglial
medium, the four lines of unsorted HPCs were further dif-
ferentiated and matured. At the final day of microglial mat-
uration, iPS-microglia or iPS-microglia 2.0 were harvested
for RNA isolation and analyzed via RNA sequencing.
At a transcriptome level, our new protocol produced
homeostatic human microglia that were virtually identi-
cal to microglia generated using our prior methods.
Principal component analysis of the full transcriptome
explained 73% of variation in all samples within PC1
(44%) and PC2 (29%) and revealed that our new
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microglia (iPS-microglia 2.0) closely cluster and are in-
terspersed with microglia differentiated using our previ-
ously published protocol, yet are highly distinct from
human CD14+ or CD14/CD16+ blood monocytes and
dendritic cells (Fig. 2a, b, Fig. 3, Additional file 3: Table
S1). Consistent with our previous findings, both
iPS-microglia and iPS-microglia 2.0 exhibit very similar
gene expression profiles to brain-derived cultured hu-
man microglia, although some differences between these
groups remain. In order to highlight important micro-
glial and monocyte enriched genes, we performed a
secondary principal component analysis with a previously-
identified microglial/monocyte focused gene set which re-
vealed a developmental component (PC1, 48% of variance)
and again shows interclustering of iPS-microglia 2.0 with
microglia generated using our previously published
approach (Fig. 2b, d). Importantly, this developmental
trajectory remains quite distinct from monocytes and
dendritic cells (Fig. 2b).
Interestingly, RNA sequencing analysis of HPCs gene-
rated using our previously published approach versus
HPC 2.0 revealed some intriguing differences between
these two populations. Based on the developmental trajec-
tory shown in Fig. 2b, these data suggest that HPC 2.0
samples are closer to microglia on the primary principle
component showing the developmental trajectory than
HPCs from our previously described protocol. Indeed
HPC 2.0 populations include lower percentages of cells
expressing the primitive HPC marker CD235a, although
both populations express equivalently high levels of an-
other primitive HPC marker; CD43 which is typically ab-
sent in definitive HPCs [17] (Additional file 2: Figure S2,
Additional file 4: Table S3). Importantly, although some
differences do exist in gene expression between these two
HPC populations, very few differences in gene expression
persist once HPCs are matured into microglia (Fig. 1, Fig.
2c, d, Additional file 5: Table S2). For example, expression
analysis comparing iPS-microglia and iPS-microglia 2.0
revealed only 55 differentially expressed genes. To deter-
mine whether these differences occur in a uniform path-
way or are indicative of important functional effects that
need to be considered, we next used Reactome 2016 gene
ontology analysis to examine these 55 genes. This analysis
revealed only three significant gene ontology pathways
(Platelet activation, signaling and aggregation_Homo
sapiens_R-HAS-76002, FDR = 0.03665; Chemokine
receptors bind chemokines_Homo sapiens_R0HSA-380,108,
FDR = 0.03665; Tryptophan catabolism_Homo sapiens_
HSA-72,140, FDR = 0.03665). The chemokine receptor
pathway is of course important for microglial function,
although this pathway was implicated by only 3 differen-
tially expressed genes: CXCL10, CCL5, and PF4. Thus, we
Fig. 1 A simplified microglial differentiation protocol can be used to produce large numbers of highly pure human microglia. Schematic showing
the process of differentiation from iPSCs through the mesoderm lineage (days 0–3) and further promoting hematopoiesis (days 3–11). Primitive
hematopoietic progenitor cells begin to appear on day 7 (black arrows) and by day 11 large numbers of round non-adherent HPCs are observed.
Floating HPCs are then transferred into new medium to induce microglial differentiation for 27 days. The last 3 days of microglial differentiation
include additional neuronal and astrocytic ligands to further educate microglia toward a brain-like, homeostatic environment. By day 38, large
numbers of highly pure microglia that stain positively for both P2RY12 and TREM2 (> 94%) have been produced and are ready for experimentation
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expect that microglial functional activity will be largely
equivalent between iPS-microglia and iPS-microglia 2.0.
Functional validation of iPS-microglia 2.0
To determine whether the functional activity of iPS-
microglia 2.0 is indeed equivalent to microglia generated
using our prior approach, we next compared phagocytic
activity of cells generated using both methods [8]. Since
the ability of microglia to clear pathogens and extracellu-
lar aggregates via phagocytosis is an important aspect of
microglial function, we exposed microglia to several diffe-
rent substrates and measured the percentage of cells
which phagocytose each substrate using an Amnis Image-
stream which combines flow cytometry and high through-
put immunofluorescence (Fig. 4). As expected, the levels
of phagocytosis differed between the three varying
substrates with beta-amyloid fibrils producing the highest
response. S. aureus bioparticles, a TLR 1,2,6 agonist
produced an intermediate degree of phagocytosis and Zy-
mosan, a TLR 2/Dectin 1 agonist from S. cerevisia induced
the lowest level of phagocytosis (Fig. 4). Importantly,
regardless of the differential response to these three
phagocytic substrates, iPS-microglia and iPS-microglia 2.0
exhibited identical rates of phagocytosis for each of the
substrates, demonstrating that this simplified differenti-
ation method does not alter this important microglial
function (Fig. 4).
iPS microglia 2.0 engraft well into xenotransplantation-
compatible MITRG mice
We previously demonstrated that iPS-microglia can engraft
and ramify, fulfilling characteristic microglia morphology
Fig. 2 iPS-microglia 2.0 are virtually identical to iPS-microglia generated using a more complex protocol. a Principle component analysis
demonstrates that iPS-microglia 2.0 (dark blue) and iPS-microglia differentiated using our previously published protocol (blue) exhibit highly
equivalent gene expression profiles that cluster closely with cultured human fetal and adult microglia (light blue and teal). Additionally, these
cells are distinct from human CD14+ monocytes (purple) and CD16+ inflammatory monocytes (pink), and dendritic cells (maroon). b Principal
component analysis using a gene list enriched for 882 microglial genes from (Gosselin et al., 2017), further demonstrates the equivalent gene
expression between iPS-microglia and fetal and adult microglia. This analysis also highlights the trajectory of differentiation from iPSCs to
Microglia and shows the separation between our protocol and monocytic and dendritic cell populations. c Volcano plot of differential expression
analysis (p < 0.001, log2(FC) > 2) between iPS-HPC and iPS-HPC 2.0 samples (top) as well as iPS-microglia and iPS-microglia 2.0 (bottom).
Significantly increased or decreased genes are shown in coral or blue respectively. d Heatmap using 882 microglial-enriched genes further
demonstrates the highly similar gene expression profiles between iPS-microglia and iPS-microglia 2.0 and the close similarity of both cell
populations to fetal and adult cultured microglia
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Fig. 3 iPS-microglia 2.0 are distinct from CD14+ and CD16+ monocytes Microglia differentiated using our published protocol are distinct from
CD14+ monocytes and CD16+ inflammatory monocytes. In order to ensure our iPS-microglia 2.0 are similarly distinct from monocytes, differential
expression analysis was computed with DEseq2. a Volcano plots of differentially expressed genes comparing genes enriched in CD16+ monocytes
(pink) with genes enriched in iPSmicroglia 2.0 (dark blue) or iPS-microglia (light blue) show many significant differences between monocytes and
microglia. Venn diagrams and comparative fold change plots of differentially expressed genes show that the vast majority of differences are identical
between iPS-microglia and iPS-microglia 2.0 when compared to CD16+ monocytes. Direct comparisons of the fold change expression level (TPM) of
every gene are shown in comparative fold change plots which demonstrate the striking similarity of differential expression when iPS-microglia and
iPS-microglia 2.0 are each compared to CD16+ monocytes. b The same is true for comparisons of iPS-microglia and iPS-microglia 2.0 with CD14+
monocytes (purple)
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and marker expression in the brains of xenotransplanta-
tion-compatible MITRG (Knock-out: Rag2; Il2rg; Knock-in:
M-CSFh; IL-3/GM-CSFh; TPOh) mice [8]. Thus, we aimed
to further validate the identity of our iPS-microglia 2.0
through intracranial transplantation of iPS-microglia 2.0
into MITRG mice, and to compare this engraftment to
equivalently transplanted iPS-microglia that were generated
using our previously described differentiation method. In
each case, fully mature microglia were transplanted into the
hippocampus and overlaying cortex of adult mice which
were sacrificed after 2months for histological examination
of morphology and key marker expression. Both
iPS-microglia and iPS-microglia 2.0 can be identified within
the mouse brain via expression of the human-specific nu-
clear marker, Ku80 (Fig. 5, green). Importantly, regardless
of the differentiation method, transplanted human micro-
glia display typical microglial morphology, extending com-
plex branching processes. Both iPS-microglia and
iPS-microglia 2.0 also express the microglial/monocyte
marker Iba1 (Fig. 5, Overlay images C, G, K, & O, red) and
the homeostatic microglial marker P2RY12 (Fig. 5 Overlay
images, D, H, L, & P, red) in both cortex and hippocampus,
indicating that these cells engraft well and remain homeo-
static. Transplanted iPS-microglia 2.0 also exhibit the tiling
and distinct niches typical of in vivo microglia, and can be
seen interspersed with the endogenous population of
mouse microglia (Fig. 5, arrows indicate Iba1+/Ku80−
mouse cells). Taken together, these findings further demon-
strate that iPS-microglia 2.0 are equivalent to microglia
generated using our previously published protocol and can
be readily transplanted into MITRG mice to enable in vivo
studies of human microglia.
Small molecule activation of TGFβ signaling produces
microglia-like cells that are similar, but transcriptionally
distinct from iPS-microglia 2.0
TGFβ1 is a crucial astrocyte-derived cytokine that pro-
motes microglial homeostasis [15, 18]. TGFβ1 signaling
results in phosphorylation of smad2/3 and ultimately
up-regulates expression of CX3CR1, an important receptor
for microglial function and survival [19, 20]. Indeed, removal
of either TGFβ1 or CX3CR1 greatly decreases microglia
populations in murine models [15, 20]. As we have pre-
viously shown, removal of TGFβ1 from iPS-microglia
Fig. 4 iPS-microglia 2.0 exhibit equivalent substrate-dependent phagocytosis. iPS-microglia and iPS-microglia 2.0 were exposed to fluorescent beta-
amyloid fibrils, pHrodo tagged S. aureus, or pHrodo tagged Zymosan A bioparticles from S. cerevisiae. Quantification of the percent of total cells with
positive fluorescent signal and the mean fluorescence intensity of that signal is shown on the left. No significance differences were found between
each differentiation type, demonstrating the equivalent functional activity of microglia generated by these two differentiation paradigms. Representative
images of phase, CD45 staining, and the fluorescent signal of beta-amyloid (top), S. aureus (middle), and Zymosan A (bottom) are shown on the right.
One representative image of 10,000 quantified images is shown for iPS-microglia 2.0 (top of each set) and iPS-microglia (bottom of each set)
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for even 24 h also results in dramatic changes in the
microglial transcriptome, including down-regulation of
homeostatic signatures [8].
In order to increase cost-efficiency during iPS-microglia
2.0 differentiation, we attempted to replace recombinant
TGFβ1 with Inducer of Definitive Endoderm 1 or 2 (IDE1,
IDE2). As its name suggests, IDE has been used to differ-
entiate iPS cells into definitive endoderm through activa-
tion of TGFβ signaling [21]. More specifically, IDE1/2
have been shown to induce phosphorylation of the down-
stream TGFβ signaling molecule smad2 [21]. This led us
to hypothesize that IDE1 or IDE2 could induce expression
of microglial genes in an equivalent fashion to recombi-
nant TGFβ if added after mesoderm formation and
hematopoiesis.
To determine whether IDE1 or IDE2 could replace re-
combinant TGFβ in our differentiation protocol, HPCs
harvested on day 10 were placed into microglia differen-
tiation media and varying concentrations of IDE1 or
IDE2 (1 μM, 10 μM, 100 μM, 1000 μM) were added in
place of TGFβ (Fig. 6a). During the first 4 days of micro-
glia differentiation we used an Incucyte live imaging
system to examine the growth kinetics of each group to
provide an initial assessment of the effects of varying
IDE concentrations. Surprisingly, this analysis demon-
strated that IDE2, regardless of concentration, impaired
normal microglial proliferation and thus was not studied
further. In contrast, IDE1 was able to mimic the typical
growth kinetics observed in control cells differentiated
in parallel and maintained in normal TGFβ-containing
medium. Because the control TGFβ microglial growth
curve fell between the 10 μM and 1 μM IDE1 curves, we
next adjusted the IDE1 concentrations to include a 5 μM
dose. In addition, two higher concentrations of IDE1
Fig. 5 Transplanted iPS-microglia 2.0 display typical microglial markers and morphology comparable to our previously described iPS-microglia.
Adult 2 month old MITRG mice were transplanted with (a-d & i-j, top rows) iPS-microglia 2.0 or (e-h & m-p, bottom rows) iPS-microglia. Brains
were harvested 2 months post-transplant. Representative images of cortical (a-h) and hippocampal (i-p) transplanted cells demonstrate complex
process ramification and typical tiling. Transplanted iPS-microglia and iPS-microglia 2.0 both express Iba-1 (Overlay images c, g, k, & o, red) and
the microglia specific marker, P2RY12 (Overlay images d, h, l, & p, red) and demonstrate human nuclear staining (Ku80, green). Additionally,
transplanted human microglia can be seen integrating and tiling with the endogenous mouse microglia population (Arrows indicate
Iba1+/Ku80- cells)
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(50 μM, and 500 μM) were also included as the growth
kinetic measurements suggested that these concentra-
tions might further increase the yield of microglia.
All groups were differentiated in parallel for the
complete 38 day paradigm before RNA-sequencing was
performed. To compare these new samples with our
iPS-microglia, fetal and adult microglia, and other cell
types, we generated a correlation matrix (Fig. 6b) which
demonstrated that IDE1 iPS-microglia remain distinct
from monocytes and dendritic cells and cluster closely
with our other iPS-microglia. IDE-treated cells also
exhibited strong expression of key microglial genes in-
cluding CSF1R, P2YR12, TREM2, OLFML3, HEXB, and
C1Q (Additional file 6: Table S4). Based on the hierarch-
ical clustering within our correlation matrix (Fig. 6b), we
find that microglia differentiated in IDE1 have transcrip-
tomic profiles that are more similar to primary cultured
microglia (fetal and adult microglia). One possible ex-
planation for this finding is that IDE1 may have greater
stability within the culture media than TGFβ1 and thus
provide a more uniform and consistent activation of
TGFβ signaling pathways. Alternatively, IDE1 could po-
tentially provide increased specificity by only targeting
smad2 signaling. To further understand the comparative
effects of IDE1 versus TGFβ1 we further compared these
groups of iPS-microglia using DEseq2 to highlight any dif-
ferentially expressed genes (Additional file 6: Table S4).
Interestingly, gene ontology analysis of these differentially
expressed genes revealed only five pathways that were sig-
nificantly enriched between these two populations of micro-
glia (Fig. 6c), again showing their strong similarity. Taken
together these data suggest that IDE1 can indeed be used in
place of TGFβ1, although researchers should also consider
these differentially altered pathways and genes in there deci-
sion whether or not to use this further modified approach.
Discussion
In recent years, the importance of microglia in brain de-
velopment, homeostasis, and disease has become in-
creasingly clear. Because microglia have been implicated
in many neurological diseases and injuries including
neurodegeneration, traumatic brain injury, and develop-
mental disorders, several groups have developed
methods to try to make these cells more accessible for
neurological research. Until recently, microglia could
only be studied through brain biopsies, postmortem ana-
lysis, or in animal models. Although mouse models of
neuroinflammation have been extremely useful in unco-
vering important new findings, many differences exist be-
tween human and murine microglia. For example, one
recent study identified several co-regulated myeloid gene
expression modules that occur in human AD, but do not
occur in AD mouse models [22]. Likewise, many differ-
ences exist between the murine and human complement
system that is closely linked to neurodegenerative diseases
including AD [6]. At least two microglial-expressed AD
risk genes, CR1 and MS4A4A, have no murine ortholog,
further highlighting the challenges of studying the role of
microglia in human disease using mouse models alone.
To study human microglia, some highly skilled groups
have turned to human biopsy material. Working closely
with neurosurgeons, these researchers have developed
methods to isolate human microglia from brain tissue
removed during a surgical resection of a brain tumor or
Fig. 6 The small molecule compound IDE1 can be used in place of TGFβ-1 to produce iPS-microglia. IDE1 and IDE2 were added to microglia
cultures in place of TGFβ-1 at the indicated concentrations. a Growth curves from the first 3.5 days of microglial differentiation show that IDE2 is
insufficient to allow proliferation of these cells. In contrast, IDE1 (blue) at lower concentrations shows similar growth kinetics to TGFβ control cells
(green). b Correlation matrix displaying all samples analyzed in this manuscript shows cells differentiated with IDE1 cluster closely with iPS-microglia
2.0 and are actually more similar to fetal and adult microglia than TGFβ control microglia. c Gene ontology analysis using the Reactome database
displays differences between IDE1 treated cells and TGFβ (FDR < 0.001, FC > 2). Enrichment in IDE samples reflects an increased expression of genes
within this GO family in IDE1 treated cells
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intractable epileptic foci [5, 7, 23]. Using this approach,
researchers have uncovered exciting data and greatly
advanced our understanding of the human microglial
transcriptome. However, epileptic foci and tumor tissue
induce neuroinflammation and despite best efforts to
avoid isolating microglia from ‘diseased-effected tissue’ it
is likely that microglia isolated from these patients ex-
hibit considerable variation and alterations in activation
state [24, 25].
Another strategy for studying human microglia involves
the isolation of microglia or their nuclei from postmortem
brain tissue. Using this approach, researchers have unco-
vered important age-related differences in the human
microglial transcriptome [26]. Still, it remains unclear
whether the agonal state that precedes death, inflamma-
tory co-morbidities, or post-mortem delay might influence
microglial gene expression. In the case of Alzheimer’s dis-
ease, most patients die from an accompanying infectious
disease such as Pneumonia [27, 28]. Interestingly, animal
models of Pneumonia exhibit significant changes in brain
microglial activation state [29, 30]. Thus, it is likely that
this and other common infectious co-morbidities can
complicate the interpretation and analysis of postmortem-
isolated human microglia.
Given the considerable challenges with isolation and
study of postmortem or biopsied human microglia,
several groups, including our own, developed protocols
which utilize the power of stem cells to produce human
microglia in vitro [8]–[13]. These methods have begun
to enable more detailed mechanistic studies of human
microglia by allowing controlled experimental treat-
ments, drug testing, and genetic manipulation. However,
the currently existing protocols are relatively compli-
cated and can be challenging to adopt, especially for
groups with little prior stem cell experience. Thus, to
address this challenge we developed and validated the
greatly simplified and refined method presented here. In
comparing this new method to our previously published
differentiation protocol, we confirm that iPS-microglia
2.0 show highly similar RNA transcript profiles to
iPS-microglia as well as primary fetal and adult micro-
glia. In addition, iPS-microglia 2.0 remain distinct from
blood monocytes and importantly display largely the
same differentially expressed genes between microglia
and monocytes as our previously published
iPS-microglia.
To further investigate and characterize iPS-microglia
2.0 we functionally validated these cells by examining
phagocytosis of three different substrates; Staphylococcus
aureus, Zymosan A, and fibrillar beta-amyloid. While
each substrate exhibited differential degrees of phagocy-
tosis, these levels were equivalent between our pre-
viously described iPS-microglia and iPS-microglia 2.0.
Lastly, to determine whether iPS-microglia 2.0 can also
be used for in vivo studies, we transplanted microglia
derived via both methods into xenotransplantation-com-
patible MITRG mice, confirming that engraftment, in
vivo morphology, and marker expression was equivalent
between iPS-microglia and iPS-microglia 2.0. Taken to-
gether, these functional and in vivo experiments further
support the conclusion that microglia generated via
these two methods are virtually identical.
In addition, we tested IDE1 as a small molecule agonist
of TGFβ signaling cascades. To this end, we confirmed
that substitution of TGFβ1 with IDE1 produced cells that
are similar to iPS-microglia 2.0, and additionally highly
similar to adult and fetal primary microglia. We have pro-
vided differential gene expression analysis to highlight the
important differences between IDE- and TGFβ1-treated
iPS-microglia 2.0, which researchers should consider
when deciding whether to use TGFβ or cost-saving IDE1
for iPS-microglia generation.
Conclusions
In summary, we provide detailed methods and validation
of a greatly simplified protocol to produce significantly
increased numbers of pure human microglia. The
RNA-sequencing, functional validation, and transplant-
ation studies presented here clearly demonstrate that
highly pure populations of human iPS-microglia can be
generated via this greatly simplified protocol. We antici-
pate that this streamlined and highly reproducible proto-
col will enable many more interested researchers to now
study human microglia, leading to further breakthroughs
in this field.
Methods
Ethics Statement: All experiments were carried out ac-
cording to human stem cell (hSCRO) and animal use
(IACUC) protocols that were approved by the University
of California, Irvine.
Find the complete catalog of materials and catalog
numbers in Additional file 7: Table S5.
Simplified differentiation of iPSCs to HPCs
Improved and simplified differentiation of iPSCs to
CD43+ primitive hematopoietic progenitor cells (HPCs)
is achieved using Stem Cell Technologies STEMdiff™
Hematopoietic Kit (Catalog # 05310). On day − 1,
feeder-free iPSCs that have been expanded in TeSR-E8
media are passaged with ReLeaSR (STEMCELL tech-
nologies) into mTeSR E8 medium with 0.5 μM Thiazovi-
vin onto matrigel coated (1 mg/mL) 6-well plates
(Corning Costar). Small aggregates of ~ 100 cells each
are plated at 10–20 aggregates per cm2. The initial
plating density is critical as higher density impairs meso-
derm differentiation and lower density decreases yield.
Thus one can plate iPSCs at 2–3 different densities and
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select the wells on day 0 that have optimal density to
proceed with. When approximately two 100 cell colonies
per cm2 have been achieved, replace TeSR-E8 medium
with medium A (Basal medium plus Supplement A at
1:200 dilution, 2 mL per well of a 6-well). On day 2 (48 h
after original media change), do not fully change media,
but rather replace 50% medium A, 1mL per well of a
6-well. On day 3, carefully remove all media by tilting the
plate to one side and aspirating from the edge. Then add 2
mL/well medium B (Basal medium plus supplement B at
1:200). Without removing media, supplement with 1mL/
well of medium B on days 5, 7, 9. On day 10 and again on
day and 12, non-adherent cells may be collected. To main-
tain purity, do not wash cells off the well, but merely re-
move medium with non-adherent cells carefully and
centrifuge 300 x G 5min. After centrifugation, replace con-
ditioned medium back to each well and add 1mL fresh
medium B if further collection on day 12 will be completed.
FACS analysis has confirmed that these non-adherent
cells represent highly pure populations (> 93%) of
CD43+ hematopoietic progenitor cells (Additional file 2:
Figure S2). Importantly, simply collecting the floating
cells is all that is required to isolate large numbers of
highly purified CD43+ cells. No FACS or MACS isola-
tion is required as identical microglia are produced using
any of these three methods (Additional file 1: Figure S1).
However, because the cells are not being sorted for pur-
ity, the collection of non-adherent cells must be carefully
completed. Do not spray medium over adherent cells to
wash as this will loosen cells which are not CD43+ and
decrease culture purity.
At this point, HPCs may be frozen at 2–4 million cells
per mL in BamBanker (Wako). If frozen, HPCs should be
thawed directly into microglial differentiation medium
with cytokines (below) and plated onto Matrigel-coated
plates at 10,000 cells per cm2. We typically find that viabil-
ity post-thaw is between 70-95%, with improved viability
when greater densities of HPCs are thawed together.
Updated differentiation of CD43+ HPCs to iPS-microglia
2.0
Volumes specified for 35mm well (1 well of a 6-well plate).
On day 0 of iPS-microglia differentiation, plate HPCs
at 10,000 cells per cm2 onto 1 mg/mL Matrigel-coated
plates (100,000 per 35 mm well). Plate cells into
iPS-microglia medium at 2 mL per 35 mm well: DMEM/
F12, 2X insulin-transferrin-selenite, 2X B27, 0.5X N2,
1X glutamax, 1X non-essential amino acids, 400 μM
monothioglycerol, 5 μg/mL insulin. Immediately before
use, microglial medium should be supplemented with
100 ng/mL IL-34, 50 ng/mL TGFβ1, and 25 ng/mL
M-CSF (Peprotech) taken from single-use frozen ali-
quots (important: do not freeze/thaw these cytokines as
it will significantly impair differentiation and yield as
well as induce activation. It is crucial to thaw cytokines
immediately before use). Throughout the differentiation
of HPCs to microglia, these cells will predominantly
grow non-adherently. On days 2, 4, 6, 8, and 10, add 1
mL fresh media plus freshly thawed tri-cytokine cocktail.
Cytokines are diluted to the concentrations listed above
before adding to conditioned medium. Do not fully re-
move media during the microglial differentiation as the
cells secrete paracrine cytokine signals and will not
properly differentiate upon removal of those. On day 12,
collect 6 mL media from each 35mm well leaving 1 mL
conditioned medium on the plate. Centrifuge non-adher-
ent cells in removed medium for 5 min at 300 x G. As-
pirate medium and resuspend non-adherent cells in 1
mL fresh medium plus tri-cytokine cocktail per 35 mm
well and add back to the same well which contains the
1 mL conditioned medium. Continue to supplement
media (1 mL) on days 14, 16, 18, 20, 22, and 24. On day
25, centrifuge cells leaving 1 mL conditioned media per
35 mm well as on day 12. On day 25, cells should be re-
suspended in microglia media plus 100 ng/mL IL-34, 50
ng/mL TGFβ1, 25 ng/mLM-CSF, 100 ng/mL CD200 and
100 ng/mL CX3CL1 to further mature microglia and en-
sure homeostasis. On day 27, feed cells with microglia
media with five cytokine cocktail (1 mL per well). On
day 28 cells collected for RNA sequencing or use for
transplantation or functional assays. If necessary, cells
can be maintained for 1–2 additional weeks via media
supplementation as above, although longer-term culture
is not advised.
Isolating RNA
Total RNA was isolated from cells using RNeasy Mini
kit (Qiagen). Approximately 1 million iPS-microglia cells
were lysed in RLT buffer and RNA was isolated per
manufacturer’s instructions with DNAse treatment (10
min) and increased spin times to maximize yield (16,000
x G for 1.5 min). RNA integrity was measured using the
Bioanalyzer Agilent 2100. All libraries were prepared
from samples with RNA integrity values ≥9.7. 500 ng
RNA per sample was used to create RNA-seq libraries
through the Illumina TruSeq mRNA stranded protocol.
Each sample was then sequenced in the Illumina HiSeq
4000 platform.
RNA sequencing analysis
RNA sequencing read integrity was verified using
FastQC. BBDuk was used to trim adapters and filter out
poor quality reads [31]. Reads were aligned to the
GRCh.38.12 human transcriptome using Kallisto [32].
Lowly expressed genes (expression count summed over
all samples < 10) were removed before differential ex-
pression analysis. Differential Expression of TPM was
calculated using DESeq2 [33]. An FDR cutoff of 0.001
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and fold change of at least 2 was used to determine dif-
ferentially expressed genes (Additional file 3: Table S1,
Additional file 4: Table S2, Additional file 5: Table S3,
Additional file 6: Table S4). Visualizations were con-
structed in part using R in addition to the Genialis visual
informatics platform (app.genialis.com) [34]. Gene ontol-
ogy analysis was performed using EnrichR.
Phagocytosis assay
Phagocytic activity of iPS-microglia was examined using
the the Amnis Imagestream (Millipore) to combine im-
munofluorescence and flow cytometry. iPS-microglia or
iPS-microglia 2.0 were treated with either 1 μg/mL
pHrodo tagged zymosan A beads, 20 μg/mL S. aureus, or
2 μg/mL fluorescent beta-amyloid (Anaspec). After
allowing 1 h at 37 degrees for phagocytosis, microglia
were resuspended in cold FACS buffer (DPBS, 1% BSA,
0.5 mM EDTA) and stained for 30 min at 4 degrees with
1:100 anti-CD45 (Biolegend, clone HI30) and Zombie-
violet live/dead stain. 10,000 events were captured for
each sample which were gated for in focus, live cells be-
fore analysis. IDEAS software was used to generate
masks of internalized signal (substrate within CD45) and
percent of cells with internalized substrates were calcu-
lated as well as mean fluorescent intensity which
remained constant for each cell type.
Animals
All animal procedures were conducted in accordance
with the guidelines set forth by the National Institutes of
Health and the University of California, Irvine Institu-
tional Animal Care and Use Committee. The MITRG
mouse was purchased from Jackson Laboratories (stock
#017711); briefly, this strain was developed on a BALB/c
background containing two knockouts alleles: Rag2−
(Rag2tm1.1Flv) and il2γc− (Il2rgtm1.1Flv); and three humanized
knock-in alleles: hCSF-1 (Csf1tm1(CSF1)Flv), h-IL-3/GM-CSF
(Csf2/Il3tm1.1(CSF2,IL3)Flv), and hTPO (Thpotm1.1(TPO)Flv). All
mice were age and sex matched and group housed on a 12
h/12 h light/dark cycle with food and water ad libitum.
Adult intracranial transplants
All mouse surgeries and use were performed in strict
accordance with approved NIH and AALAC-certified
institutional guidelines. Direct intracranial injections of
iPS-microglia into the cortex and hippocampus were
performed on adult MITRG mice. Briefly, adult mice
(2–3 months old) were anesthetized under continuous
isoflurane and secured to a stereotaxic frame (Kopf).
Using a 30-guage needle affixed to a 10 μL Hamilton
syringe, mice received 2 μL of mature iPS-microglia sus-
pended in sterile 1X DPBS at 50,000 cells/μL at each in-
jection site. Transplantation was conducted bilaterally in
the cortex and hippocampus at the following coordinates
relative to bregma: anteroposterior, − 2.06 mm; dorso-
ventral, − 1.75 mm (hippocampus), − 0.95 mm; mediolat-
eral, ±1.75 mm. Cells were injected at a rate of 50,000/
30s with 4 min in between injections. The needle was
cleaned with consecutive washes of PBS, 70% (vol/vol)
ethanol, and PBS in between hemispheres and animals.
Animals were allowed to recover on heating pads before
being placed in their home cages and received 2 mg/mL
Acetaminophen (Mapap) diluted in water for five days.
Animals were perfused 2 months following surgery with
1X PBS followed by 4% paraformaldehyde, entire brains
were removed for immunohistochemistry and confocal
microscopy.
Immunohistochemistry and confocal microscopy
Fixed half brains were first cryoprotected in a 30% su-
crose and 0.05% NaN3 solution in 1X PBS for 72 h. Tis-
sue was then sectioned into 40 μm thick slices on a
freezing microtome (Leica SM 2010R), and stored in
0.05% NaN3 solution in 1X PBS as free floating wells.
For staining, tissue was blocked for 1 h in 1X PBS, 0.2%
Triton X-100, and 10% goat serum. Immediately follow-
ing blocking, sections were placed in primary antibodies
diluted in 1X PBS and 1% goat serum and incubated
overnight on a shaker at 4 °C. Sections were labeled with
combinations of anti-Ku80 (1:250; Abcam ab79220),
anti-Iba1 (1:200; Wako 019–19,741), anti-P2RY12
(1:200; Sigma HPA014518) and mounted with DAPI
Fluoromount (SouthernBiotech). Immunofluorescent
sections were then visualized and captured using an
Olympus FX1200 confocal microscope. Images represent
confocal Z-stack taken with equivalent laser and detec-
tion settings.
Additional files
Additional file 1: Figure S1. FACS and MACS sorted HPCs differentiate
into equivalent microglia as unsorted HPCs. Hierarchical clustering of all
iPSmicroglia 2.0 samples show that MACS (fuchsia) and FACS (purple)
sorting at the HPC stage has no effect on the final differentiated
microglia as these samples intercluster with iPS-microglia 2.0 produced
from floating unsorted HPCs (blue). (TIF 11571 kb)
Additional file 2: Figure S2. Both HPC and HPC 2.0 methods produce
cells with consistently high expression of the primitive HPC marker CD43.
(Top) Quantification of flow cytometry analysis from four independent
iPSC lines per method (n = 3 wells/line) reveal a similarly high proportion
of cells (> 90%) that express the primitive HPC marker CD43 following
differentiation with either our previous or currently described approach.
In contrast, two other primitive HPC markers, CD41 and CD235a, exhibit
relatively low and heterogeneous expression within this CD43+
population (Middle). Representative FACS plots demonstrating typical
CD43+ histograms (pre gated for live, single cells). Gates were drawn
based on FMO (fluorescence minus one) controls. (Bottom) Heatmap
from RNA sequencing of iPS-HPC samples shows similar gene expression
levels for CD43, CD41, and CD235a. (TIF 45670 kb)
Additional file 3: Table S1. Significantly changed genes between iPS-
microglia, iPS-microglia 2.0, CD14 monocytes, and CD16 monocytes.
(XLSX 1562 kb)
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Additional file 4: Table S3. Differential expression analysis of iPS-HPC
versus iPS-HPC2.0. (XLSX 11 kb)
Additional file 5: Table S2. Differential expression analysis of iPS-
microglia versus iPS-microglia2.0. (XLSX 80 kb)
Additional file 6: Table S4. Differential expression analysis comparing
IDE-treated microglia to TGFB control microglia or fetal and adult cul-
tured microglia. (XLSX 11597 kb)
Additional file 7: Table S5. Catelog numbers for all materials used in
this manuscript. (XLSX 45686 kb)
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